Clinical Trial Update: SU5416 in Treating Patients With Advanced or Recurrent Cancer of the Head and Neck [Phase 2]

View source ↗

Summary

Phase 2 trial evaluated SU5416 (semaxanib), an anti-angiogenic agent, in patients with advanced or recurrent head and neck cancer, carcinoma of unknown primary,…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Carcinoma of Unknown Primary
• Head and Neck Cancer
• Non-melanoma Skin Cancer

Drugs mentioned

• SU5416 (semaxanib) (semaxanib)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Carcinoma of Unknown Primary, Head and Neck Cancer | Phase 2 | Status: COMPLETED